Longwood Capital Partners
Latest statistics and disclosures from Acuta Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are IDYA, PRAX, TERN, WHWK, TNGX, and represent 78.57% of Acuta Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: IDYA (+$162M), ERAS (+$5.7M), STRO (+$5.0M), TNGX, MLTX, 4d Molecular Therapeutics In, DRUG, RVMD, TRDA, AVTX.
- Started 5 new stock positions in TRDA, AVTX, IDYA, ERAS, 4d Molecular Therapeutics In.
- Reduced shares in these 10 stocks: CDTX (-$20M), TERN (-$7.5M), , INSM, OCUL, AMLX, ZYME, INBX, CMPX, VSTM.
- Sold out of its positions in CDTX, DNTH, INBX, INSM, NUVB.WS, KTTA, VSTM, ZYME, JAZZ.
- Acuta Capital Partners was a net buyer of stock by $136M.
- Acuta Capital Partners has $301M in assets under management (AUM), dropping by 104.27%.
- Central Index Key (CIK): 0001582844
Tip: Access up to 7 years of quarterly data
Positions held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 26 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ideaya Biosciences Call Call Option (IDYA) | 53.8 | $162M | NEW | 49k | 3332.00 |
|
| Praxis Precision Medicines I Com New (PRAX) | 9.1 | $27M | +2% | 85k | 322.19 |
|
| Terns Pharmaceuticals (TERN) | 8.7 | $26M | -22% | 496k | 52.72 |
|
| Aadi Bioscience (WHWK) | 3.9 | $12M | 3.4M | 3.45 |
|
|
| Tango Therapeutics (TNGX) | 3.1 | $9.2M | +56% | 442k | 20.92 |
|
| Bright Minds Biosciences Com New (DRUG) | 2.7 | $8.2M | +32% | 112k | 72.97 |
|
| Sutro Biopharma (STRO) | 2.2 | $6.7M | +299% | 269k | 24.91 |
|
| Erasca (ERAS) | 1.9 | $5.7M | NEW | 355k | 16.18 |
|
| Surrozen Com New (SRZN) | 1.7 | $5.0M | -3% | 173k | 29.13 |
|
| Ocular Therapeutix (OCUL) | 1.7 | $5.0M | -43% | 592k | 8.47 |
|
| Compass Therapeutics (CMPX) | 1.5 | $4.5M | -22% | 849k | 5.29 |
|
| Minerva Neurosciences Com New (NERV) | 1.4 | $4.3M | 710k | 6.03 |
|
|
| Moonlake Immunotherapeutics Class Ord A (MLTX) | 1.2 | $3.6M | +223% | 192k | 18.64 |
|
| Argen Se - Sponsored Adr (ARGX) | 1.1 | $3.4M | -3% | 4.7k | 730.25 |
|
| Oculis Holding Ordinary Shares (OCS) | 0.9 | $2.6M | -3% | 98k | 26.59 |
|
| Revolution Medicines (RVMD) | 0.8 | $2.5M | +209% | 26k | 97.25 |
|
| 4d Molecular Therapeutics In | 0.7 | $2.3M | NEW | 242k | 9.31 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.7 | $2.1M | -54% | 151k | 13.90 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.7 | $2.0M | -3% | 440k | 4.47 |
|
| Design Therapeutics (DSGN) | 0.5 | $1.6M | -3% | 146k | 10.64 |
|
| United Therapeutics Corporation (UTHR) | 0.4 | $1.3M | -3% | 2.2k | 592.98 |
|
| Entrada Therapeutics (TRDA) | 0.4 | $1.1M | NEW | 89k | 12.62 |
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $908k | NEW | 61k | 14.93 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.2 | $713k | -3% | 29k | 24.66 |
|
| Maze Therapeatics (MAZE) | 0.2 | $577k | -3% | 19k | 29.85 |
|
| Unicycive Therapeutics (UNCY) | 0.1 | $381k | -3% | 58k | 6.58 |
|
Past Filings by Acuta Capital Partners
SEC 13F filings are viewable for Acuta Capital Partners going back to 2014
- Acuta Capital Partners 2026 Q1 filed May 15, 2026
- Acuta Capital Partners 2025 Q4 filed Feb. 17, 2026
- Acuta Capital Partners 2025 Q3 filed Nov. 14, 2025
- Acuta Capital Partners 2025 Q2 filed Aug. 14, 2025
- Acuta Capital Partners 2025 Q1 filed May 15, 2025
- Acuta Capital Partners 2024 Q4 filed Feb. 14, 2025
- Acuta Capital Partners 2024 Q3 filed Nov. 14, 2024
- Acuta Capital Partners 2024 Q2 filed Aug. 14, 2024
- Acuta Capital Partners 2024 Q1 filed May 15, 2024
- Acuta Capital Partners 2023 Q4 filed Feb. 14, 2024
- Acuta Capital Partners 2023 Q3 filed Nov. 14, 2023
- Acuta Capital Partners 2023 Q2 filed Aug. 14, 2023
- Acuta Capital Partners 2023 Q1 filed May 15, 2023
- Acuta Capital Partners 2022 Q4 filed Feb. 14, 2023
- Acuta Capital Partners 2022 Q3 filed Nov. 14, 2022
- Acuta Capital Partners 2022 Q2 filed Aug. 15, 2022